Overview
From early-stage senolytics to AI-driven drug discovery, these seven firms are actively writing checks in longevity biotech.
Longevity has moved from a fringe interest to a serious investment category. The market is projected to reach $67.03 billion by 2035, driven by a growing body of aging research and an aging global population.
Andy Tang, partner at Draper Associates and founding partner of Draper Dragon, sees the next decade as a turning point. He compares it to the early days of personal computing, when a handful of foundational breakthroughs made entirely new industries possible. "We will discover lots of new applications," he said. "It will almost be like someone just invented the transistor, and we can now build PCs and type 'hello world' on the screen."
Tang has spent more than two decades backing biotech, AI, and deep tech companies, including more than 15 unicorns. His longevity-adjacent investments include NewLimit, Verge Genomics, and Ten63 Therapeutics. He points to three converging forces pulling the field forward: CRISPR-based therapies moving into early clinical applications, AI-driven drug discovery made viable by declining compute costs, and precision medicine unlocked by a millionfold drop in sequencing costs since the early 2000s. "Cancer is a very individual disease," he noted, "and using the mass-produced Tylenol model for cancer treatment is similar to jamming a square peg into a round hole."
These shifts are making longevity an investable venture category, not just a scientific aspiration. Below are eight firms building strategies around aging biology, regenerative medicine, and AI-driven drug discovery.
1. Khosla Ventures
Stage focus: Seed, Series A, and Series B Check size range: $500K—$5M Healthcare focus: Epigenetic reprogramming, AI-driven drug discovery, longevity diagnostics, precision medicine, and metabolic health. Geographic focus: Global, with a strong concentration in U.S.-based startups Assets under management: more than $15 billion Currently deploying: Yes Notable healthcare portfolio companies:
NewLimit - epigenetic reprogramming
Rubedo Life Sciences - senescent cell modulation
Viome - gut microbiome & longevity diagnostics
Based out of Menlo Park, Khosla Ventures is a VC firm founded by Vinod Khosla in 2004. Some of their most noteworthy investments in the health space include Headspace, Oscar, and Sword Health. While Khosla Ventures invests in startups from seed through Series A, the sweet spot is Series A, with a typical investment of around $17.8M per deal.
2. Apollo Health Ventures
Stage focus: Pre-seed through Series A, with selective later-stage participation Check size range: $500K up to $10 million Healthcare focus: Age-related diseases, mitochondrial biology, AI-driven longevity therapeutics, and aging mechanisms Geographic focus: Investments across the U.S. and Europe Assets under management: Over $300 million Currently deploying: Yes Notable healthcare portfolio companies:
Shift Bioscience - mitochondrial restoration
Ora Biomedical - worm-model longevity drug screening
CohBar - mitochondria-based therapeutics
Headquartered in Berlin, with a U.S. hub in the Boston and Cambridge area, Apollo Health Ventures primarily invests in pre-seed, seed, and Series A stages. Samsara Therapeutics and Therini Bio were two biotech companies built completely from scratch within Apollo's Venture Lab. It also has what they've coined the "Killer Experiment," which funds a highly targeted study—or killer experiment—to test it before deploying a large amount of capital.
3. Longevity Vision Holding
Stage focus: Seed through Series B, plus their BOLD Longevity Growth Fund Check size range: $1M–$10M; BOLD makes larger growth checks Healthcare focus: Cellular reprogramming, AI in healthcare, regenerative medicine, preventive diagnostics, and organ regeneration Geographic focus: Global, with a presence across the US, Europe, and Asia Assets under management: Over $2 billion Currently deploying: Yes Notable healthcare portfolio companies:
Insilico Medicine - AI drug discovery
Freenome - liquid biopsy
LyGenesis - organ regeneration
Founded in 2018 by investor Sergey Young and based in New York City, Longevity Vision Holding focuses on several areas, including biotechnology, preventative medicine, and AI in healthcare. The company's BOLD fund, founded with Peter Diamandis in 2023, focuses on growth-stage startups. Longevity Vision Holding was also an investor in unicorn, Freenome.
4. LongeVC
Stage focus: Pre-seed through seed Check size range: $500K–$5M Healthcare focus: longevity biotechnology, aging biomarkers, AI-driven drug discovery, regenerative and preventative medicine, and platform technologies that support longevity therapeutics and healthcare infrastructure Geographic focus: Headquartered in Europe, with investments globally including the U.S. Assets under management: $40 million (raised as €35 million) Currently deploying: Yes Notable healthcare portfolio companies:
Rubedo Life Sciences - treating age-related inflammatory diseases and skin aging
Gero - aging biomarker discovery
Deep Longevity (acquired by Insilico Medicine) - AI aging clocks
LongeVC is a specialist longevity-focused VC firm that invests in longevity companies. The VC manages a portfolio of more than 25 companies, and is deploying from two funds, one worth an estimated $35 million (Fund I) and another at $120 million (Fund II).
5. Obvious Ventures
Stage focus: Series A through Series B Check size range: $5M—$12M Healthcare focus: Preventive medicine, metabolic health, reproductive health, healthy aging, and healthcare infrastructure Geographic focus: Headquartered in San Francisco; invests in US-based startups Assets under management: over $1 billion Currently deploying: Yes. Notable healthcare portfolio companies:
Virta Health - diabetes reversal and metabolic health
Modern Fertility - reproductive diagnostics
Devoted Health - tackles the systemic infrastructure of care
Obvious Ventures is a VC focused on investing in startups that combine profit with social purpose. The firm was founded in 2014 in San Francisco and describes its investment philosophy as “world positive,” backing companies designed to generate both financial returns and measurable societal impact.
6. age1
Stage focus: Pre-Seed, Seed, and early Series A Check size range: $500K–$4M Healthcare focus: Age-related disease therapeutics, senolytics, longevity biomarkers, and healthspan biology Geographic focus: U.S. first, with selective Europe presence Assets under management: $35 million Currently deploying: Yes Notable healthcare portfolio companies:
Founded by Alex Colville, PhD, and Laura Deming, age1 is an early-stage venture capital firm focused on longevity biotechnology and healthy lifespan extension. The firm is relatively new, launched only in 2023; its aim with the startups it invests in is to take a more proactive approach aimed at preventing, delaying, or treating age-related disease.
7. Andreessen Horowitz (a16z Bio)
Stage focus: Seed, Series A, and Series B Check size range: $500K-$100M Healthcare focus: AI-driven healthcare, clinical-stage biotech, digital health, healthcare infrastructure, therapeutics, diagnostics, and emerging longevity-related technologies Geographic focus: primary focus is North America; they also recently opened an office in Seoul Assets under management: over $100B+ under management across multiple funds Currently deploying: Yes Notable healthcare portfolio companies:
Loyal - canine longevity drugs
Ambience Healthcare - clinical AI
Hippocratic AI - healthcare AI
Andreessen Horowitz (a16z) is a prominent VC based in Menlo Park, California. The firm traditionally focuses on software; a16z Bio + Health is its dedicated life sciences and healthcare investment arm. The startups they invest in tend to focus on AI-driven therapeutics, tech-enabled care delivery software, or therapeutic modalities that program biological systems.
